LANDMARK ANGELS

INVESTING FOR CURES 2015

CLUB 101NEW YORK, NY

WEDNESDAY, NOVEMBER 4, 2015

Agenda

9:00– 9:45 Registration&Networking

9:45– 10:45 PresentingCompanies - ENDECE Neural - Addex Therapeutics - Nuclea Biotechnologies - Aurora BioPharma

10:45– 11:00 CompanyBreakouts&Networking

11:00– 12:00 Panel:PhilanthropiesandFoundations–AdvancesandNewApproachesinSeekingCures Keting Chu, MD, PhD | VP - Research TAP, The Leukemia & Lymphoma Society Sohini Chowdhury | SVP - Research Partnerships, The Michael J. Fox Foundation Lorraine Egan | President & CEO, Damon Runyon Cancer Research Foundation Jill O’Donnell-Tormey, PhD | CEO & Director of Scientific Affairs, Cancer Research Institute Nadim Shohdy, PhD | Director - Drug Discovery Partnerships, NYU Langone Medical Center Terry Vance | Chief Business Officer, BioMotiv

12:00– 1:00 PresentingCompanies - BioSig Technologies - Orgenesis - Stereotaxis - Agile Sciences

1:00– 1:15 CompanyBreakoutsandNetworking

1:15– 2:30 Luncheon&Keynote

TheImplicationsofAdvancesinSequencingandStemCellTechnologiesforImproved DiagnosisandTreatmentofHeritableDisease Kevin Eggan, PhD | Department of Stem Cell and Regenerative Biology, Harvard University

2:30– 3:00 Networking&Remarks

3:00– 4:00 Panel:EvolutionofPharma–FormingPartnershipswithLifeScienceCompanies Janelle Anderson, PhD | Managing Partner, CTI Life Sciences Fund Karen Akinsanya, PhD | Head - Early Stage Assessment, Merck Isai Peimer | Managing Director, MedImmune Ventures Robert Silverman | Head - Externalized Drug Discovery Partnering, Roche

4:00 Investor&CompanyNetworkingReception

Speakers

KeynoteTheImplicationsofAdvancesinSequencingandStemCellTechnologiesforImprovedDiagnosisandTreatmentofHeritableDisease

KevinEggan,PhDDepartmentofStemCellandRegenerativeBiology|HarvardUniversity

Kevin Eggan, PhD, Professor in the Department of Stem Cell and Regenerative Biology at Harvard University has garnered international recognition for his seminal work in the burgeoning field of stem cell biology and a number of high profile awards including the MacArthur Foundation "Genius Grant" in 2006. Dr. Eggan has made fundamental contributions to the fields of stem cell biology and cellular reprogramming and was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35 in 2005.

PanelPhilanthropies&Foundations–AdvancesandNewApproachesinSeekingCures

KetingChu,MD,PhDVP-ResearchTAP|TheLeukemia&LymphomaSociety

Keting Chu, VP, Research TAP at The Leukemia and Lymphoma Society (LLS), Responsible for the Therapy Acceleration program at LLS. Before joining LLS, Dr. Chu was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc before Mission. Prior to co-founding DigitAB, Dr. Chu was the co-founder and CEO of BioCubed Corporation, Vice President of Biology and head of R&D at FivePrime Therapeutics since the funding of FivePrime and the head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases.

Dr. Chu received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D In Microbiology and Immunology at University of California at San Francisco (UCSF), and conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.

SohiniChowdhurySeniorVicePresident-ResearchPartnerships|TheMichaelJ.FoxFoundationforParkinson'sResearch

Sohini Chowdhury joined the Michael J. Fox Foundation in 2005. In her current role at MJFF, Sohini oversees a team that focuses on three areas: 1) increasing engagement and developing partnerships with various stakeholders, including industry (pharma and biotech), insurance companies, and academic networks/medical groups; 2) developing and implementing strategies to improve recruitment for Parkinson's disease trials; and 3) managing the Parkinson's Progression Markers Initiative (PPMI), a $45-50 million clinical biomarker study.

Prior to joining MJFF, Sohini worked at the World Economic Forum for five years. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities. Sohini also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects. Sohini graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.

LorraineEganPresident&CEO|DamonRunyonCancerResearchFoundation Ms. Egan is President and CEO of the Damon Runyon Cancer Research Foundation. To accelerate breakthroughs, the Foundation provides the best young scientists with funding to pursue innovative cancer research. Ms. Egan is responsible for overseeing and enhancing the Foundation’s prestigious award programs; raising public awareness about the Foundation; and leading fundraising activities in partnership with its Board of Directors comprised of leaders in business, science and philanthropy.

Prior to joining the Foundation, Ms. Egan was Vice President and Assistant to the President of Mount Sinai Medical Center. Ms. Egan is a graduate of Tufts University and the University of Chicago Law School. After law school, Ms. Egan served as law clerk to the Honorable W. Arthur Garrity, Jr. of the District Court of Massachusetts. She then was an associate for five years at Ropes & Gray in Boston, practicing in the areas of litigation and health law.

JillO’Donnell-Tormey,PhDCEO&DirectorofScientificAffairs|CancerResearchInstitute

Jill O’Donnell-Tormey is Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 that is today the global leader in supporting and coordinating research aimed at harnessing the immune system’s power to conquer all cancers. She joined the organization in 1987, and has been Chief Executive since 1993.

Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University. She serves on the boards of CT Atlantic AG, a Swiss biotechnology company focused on the research and development of novel, human-derived antibodies for the treatment of cancer; Richmond University Medical Center; the Staten Island Foundation; and The City University of New York. She holds a Bachelor of Science degree in chemistry, summa cum laude, from Fairleigh Dickinson University, and a doctor of philosophy in cell biology from The State University of New York’s Downstate Medical Center.

NadimShohdy,PhDDirector-DrugDiscoveryPartnerships|NYULangoneMedicalCenter

Nadim Shohdy, PhD is the Director of the NYU Office of Therapeutics Alliances (OTA) that utilizes a novel “virtual biotech” approach to advance NYU drug discovery projects to a far more validated stage to enable greater, quality deals with biopharma, investors and disease foundations. Since its launch in 2013 OTA has transformed the way NYU de-risks its therapeutic projects and currently has a pipeline of over 15 projects in various stages of target validation, hit finding and lead optimization. Prior to co-founding OTA, Dr. Shohdy worked in NYU’s Office of Industrial Liaison with a focus on developing life science partnerships with industry.

Dr. Shohdy received his PhD with Distinction in Microbiology from Columbia University and was the 2006 Richard C. Parker Graduate Student Award recipient. Dr. Shohdy then completed his postdoctoral training at the Rockefeller University where he was awarded an NRSA Fellowship to study the cell biology of hepatitis C virus. Dr. Shohdy then joined the International AIDS Vaccine Initiative (IAVI), a non-profit product development partnership, as a research analyst in IAVI’s Innovation Fund where he was involved in developing and managing collaborative alliances with biotechnology companies and academia.

TerryVanceChiefBusinessOfficer|BioMotiv

Terry Vance is the Chief Business Officer of BioMotiv. Prior to joining BioMotiv, Mr. Vance was the Managing Member of EGS Healthcare Capital Partners, a late-stage venture capital fund that he co-founded in 2000. Mr. Vance’s portfolio included investments in Amylin Pharmaceuticals, Cerexa Pharmaceuticals (acquired by Forest Labs), Peninsula Pharmaceuticals (acquired by JNJ), Endius Corp (acquired by Zimmer) and CytoLogix (acquired by Dako). Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotech companies that included Amylin and Corixa.

As a Venture Partner of Saints Capital, Mr. Vance led the structuring and secondary purchase of a portfolio of life science companies from a leading venture capital firm, and has co-managed the portfolio since its acquisition in 2011. He serves on the boards of public company Enanta Pharmaceuticals (NASDAQ: ENTA) and private company CircuLite. For fifteen years Mr. Vance was an investment banker at Salomon Brothers and Goldman Sachs.  At Goldman Sachs, as head of Capital Markets for the Northeastern United States, Mr. Vance was an advisor to several pharmaceutical companies, including Merck, Warner-Lambert and American Cyanamid. Earlier, he managed the distribution of private equity transactions, which included Goldman’s first direct investment in a life science venture company (IGEN International). Mr. Vance holds an AB degree from Princeton University as well as an MBA degree from Stanford University. He has been a contributing editor to Diabetes Close-Up, an industry publication focused on metabolic disease, especially diabetes and obesity.

PanelEvolutionofPharma–FormingPartnershipswithLifeScienceCompanies

JanelleAnderson,PhDManagingPartner|CTILifeSciencesFund

Dr. Janelle Anderson is the Managin Partner of CTI Life Sciences Fund, a Canadian venture firm that makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage in Canada and in the U.S. Prior to CTI, Dr. Anderson was the Managing Director of the MRL Venture Fund, the corporate venture arm of Merck focused on early-stage science and breakthrough therapeutics.  She spent several years prior at Merck working for Biologics and Vaccines R&D, various roles within Finance, and as the Business Director for the newly formed, virtual External Basic Research organization.

Dr. Anderson had previously been at Carrot Capital Healthcare Ventures, a seed-stage VC firm based in Manhattan, where she built startup companies as an Entrepreneur-in-Residence. In this position she served as Acting CEO of the medical device company Access Scientific from its earliest stages of inception. She began her career as a management consultant at The Boston Consulting Group where she created growth strategies, drove operational excellence, and analyzed portfolios for pharma, biotech, and other healthcare clients. Dr. Anderson received a B.Sc. (Honours) in Chemistry from McGill University and an A.M. and Ph.D. in Chemistry from the Whitesides lab at Harvard University.

KarenAkinsanya,PhDHead-EarlyStageAssessment|Merck

Karen Akinsanya, PhD is Head of Early Stage Assessment at Merck Research Laboratories Business Development & Licensing. Karen is responsible for leading the search, scientific evaluation and due diligence on early-stage inbound and outbound business development opportunities. She also oversees the search & evaluation activities for Merck’s BD&L European hub, and serves on the Early Discovery and Development Sciences (EDDS) Leadership Team.

Karen received her Ph.D. from Royal Postgraduate Medical School, Imperial College, University of London, where she studied endocrine physiology. After post-doctoral training at Imperial College of Medicine, Royal Postgraduate Medical School, University of London and Ludwig Institute for Cancer Research, she joined Ferring Pharmaceuticals, where she gained experience in molecular and cellular biology as well as fertility and women’s health drug discovery.

IsaiPeimerManagingDirector|MedImmuneVentures

Isai joined MedImmune Ventures in 2010. He is currently or has been a board member of Adheron Therapeutics (acquired by Roche), Ambit (NASDAQ: AMBI, acquired by Daiichi Sankyo), Armaron Biosciences, Corridor Pharmaceuticals (acquired by Astrazeneca), Inotek Pharmaceuticals (NASDAQ:ITEK), and Xencor (NASDAQ: XNCR). He serves on The Ivy Foundation Biomedical Innovation Review Board at University of Virginia. Previously, Isai worked as a venture capitalist at Visium Asset Management. He was an investment banker at J.P. Morgan and a Specialty Pharmaceuticals analyst at Alliance Bernstein. Prior to Wall Street, Isai was a management consultant in the pharmaceutical and biotech industry; he began his career as a scientist at Merck.

Isai is a graduate of Emory University where he earned a B.A. in Chemistry summa cum laude, and earned his M.B.A. from the Tuck School of Business at Dartmouth.

RobertSilvermanHead-ExternalizedDrugDiscoveryPartnering|Roche

Bob Silverman leads the “Venture Partnering” team of Roche Partnering. Venture Partnering is responsible for delivering a structured and systematic approach to venture capital that translates to reach into innovation via deals originating from venture capital interactions. Prior to his current role, from 2010 – 2012 Bob was a project leader for Merger & Acquisitions, in the Strategic Partnering Group of Roche Partnering. From 2003 – 2010 Bob was a Global Licensing Director for Roche Pharma Partnering, responsible for negotiating intellectual property based licensing agreements across the full value chain of the Pharma business, ranging from enabling technologies and early phase opportunities to clinical stage assets to promoting and divesting marketed products. From 2001 – 2003 Bob was a Global Licensing Attorney. Bob joined Roche in 1993. Early in his career at Roche Bob was Senior Counsel for the US Affiliate patent department. Bob holds a degree in Chemistry from Franklin & Marshall College and a J.D. from Boston University School of Law, and is a registered patent attorney.

CompanySummaries

AuroraBioPharmaCEO:RobertBrooks,J.D.robert.brooks@aurorabiopharma.netaurorabiopharma.net

Aurora BioPharma, Inc. is a privately-held biopharmaceutical company focused on commercializing cutting edge cancer immunotherapy technology. The Company is one a handful of companies with Chimeric Antigen Receptor T-cell therapy (CAR T) in clinical trials in solid tumor, and pre-clinical trials in liquid and solid tumor . Aurora's AU-105 has completed a Phase I clinical trial in Glioblastoma and Sarcoma. In a Phase I trial, AU-105 achieved its endpoint of safety, with strong signals of tumor killing efficacy response and significant extension of survival. The Company is planning with its CAR T cell agent AU-105, a randomized multisite Phase II Glioblastoma trial, and a Phase I intracranial injection trial.

The company also has an equity interest in MedVax Technologies, Inc., its cancer vaccine, MX-225, a P53 dendritic cell vaccine, completed FDA Phase II clinical trials, in Small Cell Lung Cancer, and the company is planning a combination trial with a PD-1 antibody in lung cancer in collaboration with a major pharmaceutical company. Aurora's team is comprised of experienced research scientists and business professionals with successful track records in the industry.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

AddexTherapeuticsCEO:TimDyerChiefScientificOfficer:SoniaPoliinfo@addextherapeutics.comaddextherapeutics.com

Addex Therapeutics Ltd (“Addex”), headquartered in Geneva, Switzerland, is developing novel, orally available, small molecule allosteric modulators for neurological disorders. Addex is advancing its portfolio of drug candidates with the support of a broad set of collaborations with industry ( Janssen Pharmaceuticals and Pierre Fabre Pharmaceuticals), patient advocacy groups (MJFF, DMRF and CMTA), academic institutions and governmental organizations. While Addex drug candidates have broad potential in CNS indications, Addex is pursuing development in a number of CNS orphan indications where there are no approved treatments.

Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase IIb for PD-LID. Dipraglurant is currently being evaluated in a PET ligand receptor occupancy study in healthy subjects by the Johns Hopkins University with support from the Michael J. Fox Foundation (MJFF). Data from this study is expected around year end. Furthermore, Addex has filed for orphan drug designation for dipraglurant in PD-LID. In parallel, dipraglurant’s therapeutic use in focal cervical dystonia is being investigated in collaboration with academic institutions. A Phase II POC in focal cervical dystonia is being designed in collaboration with the Dystonia Medical Research Foundation (DMRF) and is scheduled to start early in 2016. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) has been licensed to Janssen Pharmaceuticals, inc., (a Johnson & Johnson Company) and has completed two phase II studies in schizophrenia and anxious depression. ADX71149 is currently being prepared to enter a Phase II study in epilepsy which is expected to start in 2016. Addex third program , ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase I and is currently being evaluated in Charcot- Marie-Tooth Type 1A neuropathy in collaboration with the Charcot-Marie-Tooth Association. In parallel, ADX71441 is being developed in addiction with support from the National Institute of Health. Under an ongoing collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), ADX71441 recently demonstrates robust efficacy in multiple preclinical models of alcohol use disorder. ADX71441 is currently also being evaluated by the National Institute for Drug Abuse in non-human primate models of nicotine and cocaine addiction. Data from this collaboration is expected by end of 2015 and ADX71441 Phase 1 program is expected to start in first half 2016. In addition Addex has a number of preclinical programs including mGluR3PAM/NAM for CNS disorder which is partnered with Pierre Fabre Pharmaceuticals; mGluR4PAM for neurodegenerative diseases and autoimmune disorders; mGluR2NAM for treatment resistant depression and cognitive deficits; mGluR7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes.

Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

AgileSciencesCOO:MalcolmThomasmthomas@agilesci.comagilesci.com

Agile Sciences, Inc. is a biopharmaceutical company based in Raleigh, North Carolina that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections. Agile Sciences core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action resulting in enhanced antibiotic activity. These 2-AI compounds have been shown to:

• Restore the activity of antibiotics against multi-drug resistant (MDR) Gram-positive and Gram-negative bacterial pathogens. • Inhibit and disperse bacterial communities, known as biofilms • Mitigate the acquisition of antibiotic resistance • Display a novel mode of action through inhibiting the response regulator protein of bacterial two-component systems

The antibiotics market generated global sales of $39.6 billion in 2013. Despite this very large market, there are many infections that are not treatable by marketed antibiotics due to the growing issues of antibiotic resistance. These infections are responsible for an estimated 20,000 deaths in the United States each year with an associated $20 billion in direct health care costs and $35 billion in lost productivity. Antibiotic resistance has become one the greatest health care challenges for the future, having a significant impact on patient mortality and costs to health care systems. Regardless of these challenges, very few new classes of antibiotics that act via a novel mechanism of action have been introduced over the past two decades. Therefore, a compelling unmet need exists for an entirely new approach toward controlling bacterial infections and the growing trend of antibiotic resistance.

Agile Sciences’ 2-AI compounds have the potential to revitalize the antibiotic market by restoring drug resistant bacterial strains to many existing classes of antibiotics to address this large unmet medical need. The company is currently focused on three therapeutic areas that involve difficult-to-treat infections: 1) treatment of Gram-negative MDR bacterial infections; 2) treatment of lung infections in cystic fibrosis (CF) patients; and 3) treatment of chronic wound infections.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

BioSigTechnologiesExecutiveChairman:KennethL.LondonerVPCorporateFinance&InvestorRelations:BrianMcLaughlinDirectorofAdministration:LoraMikolaitisklondoner@biosigtech.com,bmclaughlin@biosigtech.com,lmikolaitis@biosigtech.combiosigtech.com

BioSig Technologies, Inc. (OTCQB: BSGM), headquartered in Minneapolis, MN, is developing the PURE EP™ System, a surface electrocardiogram and intracardiac multichannel recording and analysis platform designed to enable crucial clinical decision-making during electrophysiology procedures in real-time. The PURE EP System acquires and displays high-fidelity cardiac signal recordings and provides guidance in identifying catheter ablation targets - areas of cardiac tissue that are responsible for a heart rhythm disturbance (arrhythmia). The Company is focused on improving outcomes of complex catheter ablation treatments for Atrial Fibrillation (AF) and Ventricular Tachycardia (VT), the very common and often life-threatening arrhythmias. BioSig is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, Mayo Clinic, and UCLA Cardiac Arrhythmia Center; and its Scientific Advisory Board is comprised of top thought leaders in the field of electrophysiology.

According to the American Heart Association, AF currently affects approximately 3 million Americans. By 2050, this number is expected to more than double. AF costs the US healthcare system an annual $26 billion. The patients’ health-related issues can be even more devastating: 3x more likely to undergo multiple hospital admissions, 5x increased risk for stroke, and 3x increased risk of heart failure. Ventricular arrhythmias account for more than 350,000 sudden cardiac deaths annually in the US. Catheter ablation has been proven highly successful and a preferred treatment for many arrhythmias; however, ablation for AF and VT is mainly empirical and recurrence rates remain high. Ablation treatments for AF and VT are still on the rise – numbers are forecasted to grow at 10.5% annually from 2012 to 2017. With the increasing need for these treatments, comes the greater demand for innovative and effective technologies. BioSig’s PURE EP System is designed to provide clarity of data and real-time information unobtainable from any other system on the market today.

Analysts forecast the global market for EP devices will grow at a 12.1% compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019 - making it one of the fastest growing medical device segments. The M&A activity in the EP space is aggressive, and small companies with innovative technologies earn large premiums. BioSig’s technology has attracted a proven management team and a world-class independent Board of Directors that includes former top executives from the key players in the field.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

ENDECENeuralCEO&Co-Founder:JamesYarger,PhDJames.Yarger@endece.comendece.com

ENDECE Neural, LLC, headquartered in Mequon, Wisconsin, has discovered and is developing a small molecule compound (NDC-1308) that has the ability to induce remyelination of axons in demyelination diseases such as multiple sclerosis (MS). The company’s management has a track record of successfully taking products from the laboratory through FDA approval and commercial release. Supporting the company’s management team, ENDECE Neural has created a world-renowned team of leading MS researchers, clinicians, CRO’s (including pharmacology, toxicology, DMPK, and clinical) and business managers to bring NDC-1308 into the clinic for treating MS patients.

MS is a progressive disease that exposes nerves in the brain and spinal cord by destroying the nerves’ protector, the insulating cover called the myelin sheath.  Some typical symptoms include progressively worsening fatigue, pain, cognitive issues, depression, spasticity and loss of motor control. The disease strikes people in the prime of their lives with an average onset age of 34. There are over 400,000 people in the US with MS and over 2.5 million people worldwide. There is no cure for MS and there can be no cure without the ability to remyelinate the demyelinated nerves. Unlike current therapies for MS that only slow disease progression, NDC-1308’s ability to induce remyelination may lead to restoration of lost functions and reversal of the disease in MS patients. The global market for current MS drugs is $15 billion and is projected to reach $20 billion by 2018 (Evaluate Pharma 4/2013). Multiple currently marketed MS drugs have annual sales in excess of $2 billion. It is anticipated that a drug for inducing remyelination in MS patients could be most effective in combination with current therapies (eg current therapies to slow progression plus a remyelination drug to further reduce progression and restore function). Therefore a remyelination drug has the potential to double the current market size.

NDC-1308 was discovered in-house and is protected by both composition-of-matter and use patents (3 US patents issued and 14 foreign patents issued; the patent application for use in treating MS was approved in Europe and is pending in US). NDC-1308 is in late preclinical studies and is poised for Phase 1 clinical trials. ENDECE Neural is planning nonclinical IND-enabling studies for mid-2016 followed by an IND submission to the FDA at the end of 2016. The company anticipates Phase 1 trials in healthy volunteers beginning in early 2017. Phase 1 clinical studies will take approximately 1 year. The company’s business strategy is to develop NDC-1308 up to or through Phase 1 clinical studies and then license NDC-1308 to a third party to continue clinical development. In exchange for the license, the licensor would pay ENDECE Neural an upfront payment, contingent payments if certain developmental benchmarks are met, and a double digit royalty on eventual drug sales. ENDECE Neural is already in early discussions with multiple pharmaceutical companies that are interested in licensing NDC-1308.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

NucleaBiotechnologiesCEO:PatrickMuracaBoardMember:CharlesStetsonnucleabio.com

Nuclea Biotechnologies is a diagnostic development group that specializes in specific tests to predict the outcome of individuals with cancer and metabolic disease. The company has been in existence for approximately 10 years. The company's IP estate is a comprehensive overview of diagnostic based develop tests in the areas of breast cancer, prostate cancer, colon cancer, and lung cancer. We have also focused on the development of new tests to help manage type II diabetes and metabolic syndrome which includes cardiovascular disease. The company maintains clinical laboratories in both it's Cambridge facility as well as in it's Pittsfield facility in specializes in immunohistochemistry, ELISA-based technology and mass spectroscopy technology.

The company has engaged the Center for Nanoscale Science and Engineering to help us develop new methodologies to miniaturize these diagnostic tests. We have developed a microfluidic chip-based technology that will provide a quick diagnostic results for many of the tests that the company has developed. This technology uses very little material to analyze for specific results to help manage disease. The current technology will allow for up to 300 tests to be performed on one single chip. The analysis takes anywhere from 30 seconds to two minutes to perform and is fully reimbursable in the United States. The tests consist of both basic and esoteric based diagnostic assays that will be used in the management and diagnosis of disease.

The difference between Nuclea's technology is that we can real-time from a fingerstick to result be able to enhance the patient/physician experience. The speed of the assay mingled with the companies high-volume and lucrative based tests stands Nuclea apart from other groups. The high-value Nuclea tests are able to diagnose and manage disease in a much different in quicker way than our closest competitor. We have high- value tests that are utilize for diagnosis and management in cancer and in metabolic syndrome, and will be used to enhance the patient experience. Most of Nuclea's tests are widely used in the United States and are considered standard of care. NanoDX and Nuclea have a close relationship with Dana Farber Cancer Institute, Joslin Diabetes, Brigham and Women's Hospital (cardiovascular).

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

OrgenesisCEO-NorthAmerica:ScottCarmerChiefFinancialOfficer:NeilReithingerscottc@orgenesis.com,neil.r@orgenesis.comorgenesis.com

Orgenesis Inc., headquartered in Germantown, Maryland, is a biotechnology company dedicated to curing Type 1 diabetes through a novel technology known as Cellular Trans-differentiation. Using this technology for insulin-dependent disorders, the company is developing a cell-based therapy that regenerates glucose-responsive insulin production and restores the body’s ability to regulate insulin production in response to an individual’s metabolic needs (homeostasis). Specifically, the company uses pancreatic genetic transcription factors to ‘trans-differentiate’ a human liver cell into a fully functional, glucose-responsive, insulin-producing cell (IPC). Cellular Trans-differentiation is a unique approach to regenerative medicine in that it directly converts an adult cell from one developmental lineage into a fully functional adult cell from another closely related developmental lineage (i.e. liver cell to pancreatic cell). This technique is unlike other regenerative approaches that use stem cells that rely on embryonic stages of cell growth and development and which can be associated with certain proliferative diseases.

IPCs are manufactured through GMP systems common to many other cell-based therapeutics called ‘adoptive cellular transfer’ – a process where cells are isolated, expanded and modified ex vivo and then reintroduced to a patient by infusion. In the case of IPCs, a small amount of a patient’s liver cells (~2 million) are collected via biopsy through a common outpatient procedure and then sent to an Orgenesis facility. Under highly controlled conditions and within tightly closed systems, the liver cells are initially expanded (to nearly 2 billion cells) and then ‘trans-differentiated’ into fully functional, glucose-responsive IPCs. After a final quality control analysis, the IPCs are ready for final release, immediate distribution and physician administration. Within an outpatient facility, the IPCs are infused back into the same patient’s liver via the portal vein in a procedure very similar to that currently used during islet cell transplantation.

Supported by a robust patent portfolio and with data from preclinical studies published in numerous peer reviewed scientific journals, Orgenesis is preparing for Phase 1 trials in the U.S. and Europe. Orgenesis’ platform technology has application not only to Type 1 Diabetes, but also in a range of different disease areas including other autoimmune and neurodegenerative disorders.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

StereotaxisCEO&ChairmanoftheBoard:WilliamC.MillsIIIBill.Mills@stereotaxis.comstereotaxis.com

Stereotaxis, Inc., headquartered in St. Louis, MO, is a leader in robotic navigation systems used in the treatment of cardiac arrhythmias and coronary disease. The company designs, manufactures, and markets its proprietary Epoch® Solution, for use in a hospital’s interventional surgical suite or “interventional lab”. The Epoch Solution is a robotically-enabled system to precisely control ablation catheters and other diagnostic devices and is comprised of:

– The Niobe® ES magnetic navigation system; – The Odyssey® information management solution; and – The Vdrive™ robotic navigation system.

The company believes that the Epoch Solution can transform the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency, and efficacy for catheter-based, or interventional, procedures.

Installed in 31 countries around the world, Stereotaxis’ robotic navigation technology has been adopted by some of the world’s leading centers and experts for treating cardiac arrhythmias. The company’s technology is an important advancement in the ongoing trend toward fully digitized, integrated and automated interventional labs and provides substantial, clinically important improvements over manual interventional methods, which often result in long and unpredictable procedure times with suboptimal therapeutic outcomes.

Stereotaxis technology has been used in the treatment of a variety of different types of arrhythmias, due to clinical benefits such as safety, low radiation exposure, and precise control of the catheter tip. In addition to these benefits, an increasing number of clinical studies have provided evidence of improved acute success and lower recurrence rates when using Stereotaxis technology for the treatment of ventricular tachycardia (VT). Due to the location of the arrhythmias and the anatomy of the ventricles, VT continues to be one of the most challenging conditions to treat using traditional ablation therapy. The company believes that through additional clinical research and enhanced training methods, Stereotaxis technology can become the standard of care for the treatment of VT.

Notes:

* Information contained in the above summary is provided by the presenting company. The presenting company, and not Landmark Angels, Inc., is solely responsible for its content.

EXTENDSASPECIALTHANKSTOOUR

KEYNOTE&SPEAKERS

FORTHEIRSUPPORTANDPARTICIPATION